(Total Views: 588)
Posted On: 01/21/2021 6:04:52 PM
Post# of 155038
From AMAREX website
https://17c1ff56-307b-40f2-aebf-335e9ef8b689....0d89c1.pdf
18 January 2021
It seems we have to be patient. Of course, AMAREX would be very conservative and they don't have to say when exactly but, nevertheless, they are giving themselves a very good margin
Also, not very accurate in regards to where the trial was conducted.
https://17c1ff56-307b-40f2-aebf-335e9ef8b689....0d89c1.pdf
18 January 2021
Quote:
Severe-to-Critical COVID-19 Patient Clinical Trial Reaches Full Enrollment
Germantown, MD, USA ( January 18, 2021 ) – Amarex Clinical Research, LLC, an NSF International company, announced a client’s Phase III clinical trial for patients with severe-to-critical COVID-19 symptoms reached full enrollment (390 patients) in mid December. Data analysis results are expected this quarter. The trial was conducted in the U.S., Canada, and U.K.
It seems we have to be patient. Of course, AMAREX would be very conservative and they don't have to say when exactly but, nevertheless, they are giving themselves a very good margin
Also, not very accurate in regards to where the trial was conducted.
(2)
(0)
